80 results
8-K
EX-99.1
FGEN
FibroGen Inc
27 Feb 19
Fibrogen Reports Fourth Quarter and Full Year 2018 Financial Results
12:00am
studies conducted in China were presented at the American Society of Nephrology (ASN) Kidney Week 2018 in a clinical late-breaking poster session … of life (SGRQ)) in multiple poster presentations at the American Thoracic Society (ATS) 2018 Conference
Clinical and preclinical data presented
8-K
FGEN
FibroGen Inc
26 Oct 18
Other Events
12:00am
studies of roxadustat for the treatment of anemia associated with chronic kidney disease conducted in China at the American Society of Nephrology Kidney … Studies of Roxadustat for the Treatment of Anemia Associated with Chronic Kidney Disease Conducted in China at American Society of Nephrology Kidney
8-K
EX-99.1
FGEN
FibroGen Inc
12 Nov 19
FibroGen Reports Third Quarter 2019 Financial Results
8:16am
Presented Last Friday at American Society of Nephrology 2019 Kidney Week
Plan to Submit Roxadustat U.S. NDA This Quarter
Conference Call Today at 5:00 … the past few months, culminating with the positive Phase 3 results for roxadustat reported at the American Society of Nephrology conference last week
8-K
FGEN
FibroGen Inc
21 May 18
Fibrogen Presents Latest Data from Praise Phase 2B Study of
5:04pm
at the American Thoracic Society 2018 in San Diego, California.
A copy of such press release is furnished as Exhibit 99.1 to this report and is incorporated … Latest Data from PRAISE Phase 2b Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis at American Thoracic Society” dated May 21, 2018
SIGNATURES
8-K
EX-99.1
FGEN
FibroGen Inc
6 Nov 23
FibroGen Reports Third Quarter 2023 Financial Results
4:05pm
for CIA in patients with non-myeloid malignancies in an oral presentation at the European Society for Medical Oncology Congress 2023.
FibroGen and its … Society of Nephrology (ASN) Kidney Week 2023 conference.
Presented preclinical data for the FG-3165 anti-Gal9 antibody program at the Society
8-K
EX-99.1
yr3afga
1 Mar 21
FibroGen Reports Fourth Quarter and Full Year 2020 Financial Results
4:06pm
8-K
wkdflh32dbc
11 Oct 19
Regulation FD Disclosure
11:49am
8-K
EX-99.2
ehf 9m61awe0i6bxn3nq
12 Nov 19
FibroGen Reports Third Quarter 2019 Financial Results
8:16am
8-K
EX-99.1
odann ziq
30 Jan 20
Astellas Submits Supplemental New Drug Application for Approval of
4:40pm
8-K
EX-99.1
rizjfx4zgc0 gp
11 Oct 19
Regulation FD Disclosure
11:49am
8-K
EX-99.1
73yf3p3bp
10 May 21
FibroGen Reports First Quarter 2021 Financial Results
4:07pm
8-K
EX-99.1
96uqj
8 Nov 18
FIBROGEN REPORTS third QUARTER 2018 FINANCIAL RESULTS
4:05pm
8-K
EX-99.1
dqm1hyl
7 Aug 18
Fibrogen Reports Second Quarter 2018 Financial Results
12:00am
8-K
EX-99.1
f314x8dl5x7i7nnh3als
21 May 18
Fibrogen Presents Latest Data from Praise Phase 2B Study of
5:04pm
8-K
EX-99.1
a57xlx4c4z c957aj
9 May 18
Fibrogen Reports First Quarter 2018 Financial Results
4:05pm
8-K
EX-99.1
uamtg
26 Oct 18
Other Events
12:00am
8-K
vpwrh0h15gebwlo
8 Nov 19
FibroGen Announces Positive Phase 3 Pooled Roxadustat Safety and Efficacy Results for Treatment of Anemia in Chronic Kidney Disease
2:00pm
8-K
0qx0ck3
30 Oct 18
Other Events
8:01am
8-K
i9dqxa5h1jy43z98
8 Nov 19
Regulation FD Disclosure
2:05pm
8-K
EX-99.1
e60b onfyvtgfvr
8 Jun 18
Regulation FD Disclosure
5:27pm